Swiss drugmaker Novartis says it will cut around 220 jobs in Germany as part of the planned closure of a production site in Wehr ⁠by the end of 2028. +Get the most important news from Switzerland in your inbox Novartis says the production site in Wehr, Germany, which manufactures tablets and capsules, is no longer competitive. “We are aware of the uncertainty that this announcement brings to our colleagues in Wehr,” Steffen Lang, head of production at Novartis, said in a statement. The group promises transparent and respectful cooperation with employees and the municipal authorities concerned. Novartis assures that the closure will not jeopardise patient supplies and reaffirms its commitment to Germany, where the company employs 2,600 staff at six sites. Meanwhile, Novartis has announced that it will invest €35 million (CHF32 million) in a new cancer therapy plant in Halle, Saxony-Anhalt, which is expected to be operational in 2027. Adapted from French by AI/sb How we work We …